Fortress Biotech Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fortress Biotech Inc.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
- Other Names / Subsidiaries
- Aevitas Therapeutics, Inc.
- Altamira Bio
- Avenue Therapeutics, Inc. (ATXI)
- Baergic Bio, Inc.
- Caelum Biosciences Inc.
- Cellvation, Inc.
- Checkpoint Therapeutics, Inc.
- Coronado Biosciences, Inc. (CNDO)
- Cyprium Therapeutics, Inc.
- DiaVax Biosciences
- Helocyte, Inc.
- Journey Medical Corporation (JMC)
- Mustang Bio, Inc.
- Mustang Therapeutics, Inc. (MBIO)
- National Holdings Corporation
- Oncogenuity, Inc.
- Tamid Bio, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.